Kairos Pharma Ltd. (NYSE American: KAPA), a clinical stage biopharmaceutical company, has announced new findings regarding its investigational small molecule GITR ligand agonist, KROS101. Presented at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting in Chicago, the study highlights KROS101's potential as a cancer immunotherapy. The data indicate that KROS101 exhibits strong activity in enhancing the immune system and targeting tumor cells through its dual mechanism of action. The study demonstrated that KROS101 enhances T cell function by promoting proliferation and increasing cytotoxicity, while also reducing T reg-mediated suppression. The findings suggest that KROS101 is superior to the anti-GITR antibody TRX518 in several aspects, including T cell tumor infiltration and cytotoxicity. The company plans to continue studying KROS101 and engage with the medical and scientific communities regarding these findings.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。